There are studies indicating that frataxin may act as a tumor-suppressor protein, as demonstrated by using frataxin overexpression in colon cancer models (exhibiting growth inhibition) [220] or mice with disrupted hepatocyte frataxin expression (that develop liver tumors) [221]. Here, FXN is linked to malignant colon neoplasm.